Research Topics
| Raoul HerbrechtSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patientsRaoul Herbrecht
Département d Hématologie et d Oncologie, Hopitaux Universitaires de Strasbourg, France
J Clin Oncol 20:1898-906. 2002..To assess the Aspergillus galactomannan enzyme-linked immunosorbent assay (ELISA) in the diagnosis of invasive aspergillosis (IA) in adult and pediatric oncohematologic patients...
Managing the challenges of invasive fungal infectionsRaoul Herbrecht
Int J Antimicrob Agents 27:1-2. 2006
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersionR Herbrecht
Département d Onco Hématologie, Hopital de Hautepierre, Strasbourg, France
Eur J Clin Microbiol Infect Dis 20:460-6. 2001..No renal or hepatic toxicity was observed. These results compare favourably with the results of standard treatment and suggest that ABCD combined with surgery may be a useful therapy in patients with mucormycosis...
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosisRaoul Herbrecht
Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
N Engl J Med 347:408-15. 2002..Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis...
Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin BR Herbrecht
Département d Hématologie et d Oncologie, Hopital de Hautepierre, Avenue Moliere, 67098 Strasbourg, France
Eur J Clin Microbiol Infect Dis 21:814-7. 2002..Change of treatment to posaconazole given orally at 200 mg four times/d resulted in progressive improvement leading finally to cure after 24 weeks of therapy. Treatment with posaconazole was clinically and biologically well tolerated...
Management of systemic fungal infections: alternatives to itraconazoleR Herbrecht
Department of Haematology and Oncology, Hopital de Hautepierre, 67098 Strasbourg, France
J Antimicrob Chemother 56:i39-i48. 2005..The characteristics of these new agents are reviewed to help clinicians in their decision to select an antifungal agent for their patients...
Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemiaR Herbrecht
Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
Med Mycol 43:S239-42. 2005..As these patients account for a majority of the aspergillosis cases, clinical trials on prophylaxis should not only be focused on allogeneic stem transplant recipients but also be designed for the patient with leukemia...
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer studyR Herbrecht
Department of Oncology and Hematology, Hopital de Hautepierre, Strasbourg, France
Bone Marrow Transplant 45:1227-33. 2010..No patient had a drug-related serious adverse event or discontinued because of toxicity. Caspofungin first-line therapy was effective and well tolerated in allogeneic hematopoietic SCT patients with mycologically documented IA...
The lipid formulations of amphotericin BRaoul Herbrecht
Départment d Hématologie et d Oncologie, Hopital de Hautepierre, 67098 Strasbourg, France
Expert Opin Pharmacother 4:1277-87. 2003..Lipid formulations of amphotericin B are extremely expensive. Whether the increase in cost translates into a long-term benefit for the patient is still unknown...
Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipientRaoul Herbrecht
Department of Hematology and Oncology, Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France
J Heart Lung Transplant 23:1451-4. 2004..Posaconazole may provide effective treatment for difficult-to-treat Fusarium infections...
Can combination salvage therapy for invasive aspergillosis improve patient outcome?Raoul Herbrecht
Hematology and Oncology Department, University Hospital of Strasbourg, France
Nat Clin Pract Oncol 2:186-7. 2005
Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infectionsR Herbrecht
Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
Int J Clin Pract 58:612-24. 2004..Posaconazole appears to be well tolerated over long-term administration (>1 year) and may represent an important addition to the anti-fungal armamentarium...
Voriconazole: therapeutic review of a new azole antifungalRaoul Herbrecht
Département d Hématologie et d Oncologie, Hopital de Hautepierre, 67098 Strasbourg, France
Expert Rev Anti Infect Ther 2:485-97. 2004..apiospermum, and fluconazole-resistant serious invasive candida infections (including C. krusei)...
Fungal infections in patients with neutropenia: challenges in prophylaxis and treatmentR Herbrecht
Département d Hématologie et d Oncologie, H pitaux Universitaires de Strasbourg, France
Drugs Aging 17:339-51. 2000..New antifungal agents, especially new azoles, are under development. Their broad in vitro spectrum and preliminary clinical results are promising...
Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patientsR Herbrecht
Département d Hématologie et d Oncologie, H pital de Hautepierre, Strasbourg, France
Eur J Clin Microbiol Infect Dis 20:77-82. 2001..2 micromol/l at the end of therapy. These results support the use of ABLC in the treatment of invasive fungal infections in children, including patients who have previously failed, or are intolerant of, traditional antifungal regimens...
[Visceral candidiasis]R Herbrecht
Département d hématologie et d oncologie Hôpital de Hautepierre 67098 Strasbourg
Rev Prat 51:725-30. 2001..Amphotericin B deoxycholate or in lipid formulation and fluconazole are the antifungal drugs of choice. Removal of a central venous catheter should always be discussed in candidemia...
Factors associated with overall and attributable mortality in invasive aspergillosisYasmine Nivoix
Pharmacie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
Clin Infect Dis 47:1176-84. 2008..Invasive aspergillosis is associated with high death rates. Factors associated with increased mortality have not yet been identified in a large population of patients with various underlying conditions...
[Potential clinical impact of therapeutic education in patients treated with anticancer drugs]Raoul Santucci
Hopitaux Universitaires de Strasbourg, pôle d oncologie et d hématologie, France
Bull Cancer 98:176-81. 2011..These data enlighten the importance of therapeutic education of cancer patients treated by chemotherapy...
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2Catherine Helias
Laboratory of Hematology, Hautepierre Hospital, Avenue Moliere, Strasbourg 67098, France
Cancer Genet Cytogenet 180:51-5. 2008..Gains on 9p being among the most common anomalies in PV, amplification of a gene or genes on this region may play a crucial role in the pathogenesis or evolution of PV...
Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitorsRaoul Santucci
Pharmacy, Hopital Hautepierre, Avenue Moliere, 67000 Strasbourg, France
Anticancer Res 30:963-5. 2010..Delayed elimination of methotrexate associated with serious side-effects has been attributed to the co-administration of benzimidazole proton pump inhibitors...
Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient careYasmine Nivoix
Pôle Pharmacie Pharmacologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
Curr Drug Metab 10:395-409. 2009..Therapeutic drug monitoring can help optimize treatment and prevent underdosing or overdosing of drugs. Education of patients and their families about signs and symptoms of possible drug interactions is also beneficial...
The enzymatic basis of drug-drug interactions with systemic triazole antifungalsYasmine Nivoix
Pôle Pharmacie Pharmacologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
Clin Pharmacokinet 47:779-92. 2008..These features are the basis of most interactions that occur during triazole therapy...
[New lipid formulations of amphotericin B. Review of the literature]E Andres
Service de Medecine interne et nutrition, Hopital de Hautepierre, Avenue Moliere, 67098 Strasbourg, France
Rev Med Interne 22:141-50. 2001..FUTURE PROSPECTS AND PROJECTS: Large-scale comparative clinical trials may clarify issues of relative efficacy in various forms of fungal infections...
13q deletions in B-cell lymphoproliferative disorders: frequent association with translocationStephanie Struski
Laboratoire d Hematologie, Hopital de Hautepierre, Avenue Moliere, 67098 Strasbourg, France
Cancer Genet Cytogenet 174:151-60. 2007..The very high frequency of 13q14 loss suggests that these deletions are of pathogenetic importance, but, the importance of the translocations remains to be determined...
Clinical pharmacokinetics of voriconazoleDominique Leveque
Department of Pharmacy, Hopital Hautepierre, Avenue Moliere, 67000 Strasbourg, France
Int J Antimicrob Agents 27:274-84. 2006..This review presents the published clinical pharmacokinetic data for the antifungal agent voriconazole. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed...
[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for early evaluation of treatment efficacy in advanced non-Hodgkin lymphoma of uterine corpus: a case reportAlessio Imperiale
Service de Biophysique et de Medecine Nucleaire, Hopital de Hautepierre, 1 Avenue Moliere, 67098 Strasbourg Cedex, France
Clin Lymphoma Myeloma 7:421-4. 2007..Despite a theoretic risk of severe infectious complications, chemotherapy was well tolerated and resulted in a sustained complete remission...
Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapyD Rey
Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
Eur J Clin Microbiol Infect Dis 18:137-41. 1999..In cases of Aspergillus renal abscess in HIV-infected patients, surgery is the treatment of choice, especially in the current era of highly active antiretroviral therapy...
Fatal Aspergillus fumigatus Myositis in an immunocompetent patientR M Javier
Service de Rhumatologie, Hĵpital de Hautepierre, Strasbourg, France
Eur J Clin Microbiol Infect Dis 20:810-3. 2001..Only six cases of Aspergillus myositis have been reported previously. All of them occurred in severely immunosuppressed patients and the outcome was fatal in all cases...
Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infectionsY Nivoix
Pharmacy Department of the University Hospital of Strasbourg, , 67098 Strasbourg, France
J Infect 52:67-74. 2006..Close monitoring of hepatic function is required. These approach should be evaluated in prospective trials...
Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosisRaoul Herbrecht
Hopital de Hautepierre, Strasbourg, France
Curr Med Res Opin 26:2457-64. 2010..Refractory invasive aspergillosis (IA) is a life-threatening condition. Cost of treatment, although secondary, is important if newer drugs are to be widely accepted. Posaconazole has been shown to have activity against aspergillosis...
Ventricular bigeminy associated with voriconazole, methadone and esomeprazoleJulie Scholler
Pharmacy, Hopital Hautepierre, Hopitaux Universitaires de Strasbourg, Avenue Moliere, 67000, Strasbourg, France
Int J Clin Pharm 33:905-8. 2011..Conclusion Physicians should be aware of the potential interaction between voriconazole, esomeprazole and methadone leading to arrhythmia. The inhibitory potential of voriconazole is possibly increased by esomeprazole...
Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-upStefano C H Kim
Department of Hematology and Oncology, Centre des Hôpitaux Universitaires de Strasbourg, BP 67000, Strasbourg, France
J Oncol 2010:812424. 2010..She remains in complete remission six years after diagnosis. Conclusion. Granulocytic sarcoma of the cervix is a rare entity for which early intensive AML type therapy is effective...
Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristineDominique Leveque
Department of Pharmacy Pharmacology, Hopital de Hautepierre, Strasbourg, France
Pharm World Sci 31:619-21. 2009..Ritonavir is a potent CYP3A5 isoenzyme and P-gp inhibitor. Lopinavir is also a P-gp inhibitor. Ritonavir and lopinavir might have delayed vincristine elimination. Clinicians should be aware of this possible interaction...
Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategiesR Herbrecht
Department of Hematology and Oncology, , 67098 Strasbourg, France
Ann Hematol 81:S52-3. 2002
Breakthrough invasive mould infections in patients treated with caspofunginKaty Anna Phai Pang
pôle d oncologie et d hématologie, Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, 1 Avenue Moliere, Strasbourg, France
J Infect 64:424-9. 2012..To describe and estimate the rate of breakthrough invasive mould diseases (IMD) in patients receiving caspofungin...
Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimenCécile Fohrer
Department of Haematology and Oncology, Hopitaux Universitaires de Strasbourg, Strasbourg, France
Br J Haematol 134:602-12. 2006..Forty-one (32%) infections were recorded in 26 (79%) patients. This study demonstrated that an individual dose-adjustment of ACVBP regimen was manageable in PTLD patients and favourably impacted on long-term survival...
Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISHWei Shali
, , , 67098 Strasbourg, France
Cancer Genet Cytogenet 168:133-45. 2006..Compared to other series, recurrent translocations appeared to be more numerous (25%), probably reflecting an evolution of therapeutic modalities...
Pharmacokinetic drug-drug interactions with methotrexate in oncologyDominique Leveque
Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, 67000 Strasbourg, France
Expert Rev Clin Pharmacol 4:743-50. 2011..This article summarizes reported drug-drug interactions involving methotrexate in clinical oncology with reference to the role of drug transporters that control the disposition of the antifolate agent...
Cola beverage and delayed elimination of methotrexateRaoul Santucci
Pharmacy Oncology and Hematology Department, Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France
Br J Clin Pharmacol 70:762-4. 2010..To report a case of severe delayed methotrexate elimination attributable to consumption of a cola beverage...
Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patientsR Herbrecht
, , France
J Chemother 7:103-10. 1995..In conclusion, isepamicin given once daily when combined with ceftriaxone in the treatment of febrile episodes in neutropenic cancer patients was as effective and no more toxic than amikacin...
Chronic disseminated Trichosporon asahii infection in a leukemic childM H Meyer
Institut de Parasitologie et de Pathologie Tropicale, , , 67000 Strasbourg, France
Clin Infect Dis 35:e22-5. 2002..This case report demonstrates that Trichosporon species can cause chronic disseminated disease with a pattern similar to that of disease caused by Candida species...
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trialThomas J Walsh
Immunocompromised Host Section, National Cancer Institute, Bethesda, MD 20892, USA
Clin Infect Dis 44:2-12. 2007..Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species...
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo signReginald E Greene
Massachusetts General Hospital, Boston, MA 02114, USA
Clin Infect Dis 44:373-9. 2007....
Changes in causes of death over time after treatment for invasive aspergillosisJohn R Wingard
Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610 3633, USA
Cancer 112:2309-12. 2008..Assessment of response to invasive aspergillosis (IA) therapy has been challenging in treatment trials...
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosisDavid W Denning
North Manchester General Hospital, University of Manchester, Manchester, United Kingdom
Clin Infect Dis 34:563-71. 2002..Voriconazole is efficacious in treating acute IA...
Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients?Raoul Herbrecht
Clin Infect Dis 46:886-9. 2008
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjunctsBrahm H Segal
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Clin Infect Dis 44:402-9. 2007..Finally, we discuss the implications of newer antifungal agents and diagnostic adjuncts in the design of future clinical trials to evaluate prophylaxis and early prevention strategies...
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Oliver A Cornely
1st Dept of Internal Medicine, University of Cologne, Germany
Clin Infect Dis 44:1289-97. 2007..Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day, but clinical efficacy data for higher doses are lacking...
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of AmericaThomas J Walsh
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
Clin Infect Dis 46:327-60. 2008
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)Denis Caillot
Hematology Department, Dijon University Hospital Center, Dijon, France
Cancer 110:2740-6. 2007..Invasive aspergillosis (IA) has a poor prognosis in immunocompromised patients. Combinations of drugs that act on different targets are expected to improve the clinical efficacy of separate compounds...
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosisJohan Maertens
Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
Cancer 107:2888-97. 2006..Interest remains as to whether caspofungin, in combination with other antifungal classes, can improve the efficacy against IA...
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaBertrand Coiffier
Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
N Engl J Med 346:235-42. 2002..We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma...
Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patientsJohn E Bennett
Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Clin Infect Dis 36:S117-22. 2003....
Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groupsJohn E Bennett
Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Clin Infect Dis 36:S123-7. 2003....
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulationsJane P Barrett
Jane Barrett Teaching and Consultancy, Cambridge, UK
Clin Ther 25:1295-320. 2003..Future trials in patients with proven fungal infection should control for factors such as premedication, infusion rates, fluid preloading, sodium/potassium supplementation, and concomitant medication...
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphomaHerve Tilly
Department of Hematology, Centre Henri Becquerel, 76038 Rouen, France
Blood 102:4284-9. 2003..004). Despite higher toxicity, the ACVBP regimen, used as first-line treatment for patients with poor-risk aggressive lymphoma, is superior to standard CHOP with regard to both event-free survival and overall survival...
A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999Olivier Lortholary
, Institut Pasteur, , Paris, France
J Antimicrob Chemother 54:456-64. 2004..08-0.80)]. Severe renal insufficiency was associated with a higher probability of death [OR = 8.77 (1.97-38.97)]. CONCLUSIONS: Our results emphasize factors associated with the antifungal therapeutic decision and with the outcome of IFI...
Diagnosis of IPA in HIV: the role of the chest X-ray and radiologistUta Zaspel
Institut fur Radiologie, Charite Universitatsmedizin Berlin, Campus Mitte, Schuhmannstr 20 21, 10117 Berlin, Germany
Eur Radiol 14:2030-7. 2004..For internists with regular exposure to HIV patients, chest films do not provide information essential for the verification or differentiation of potential IPA...
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin BFritz Offner
UZ Gent, Ghent, Belgium
Antimicrob Agents Chemother 48:4808-12. 2004..3%) patients, and hypokalemia was seen for 13 (39.4%). We conclude that liposomal nystatin can be effective for salvage therapy of invasive aspergillosis. Infusion-related adverse events have been observed frequently...
Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 casesHouria Mouas
Service des Maladies Infectieuses et Tropicales, , Paris, France
Clin Infect Dis 40:1141-7. 2005..Treatment was generally well tolerated. CONCLUSIONS: Long-term voriconazole treatment is a new therapeutic option for invasive aspergillosis with bone involvement...
Risk factors for Gram-negative bacterial infections in febrile neutropeniaCatherine Cordonnier
Hematology Department, Henri Mondor Hospital, 94000 Creteil, France
Haematologica 90:1102-9. 2005..The objective of this study was to evaluate the risk of Gram-negative bacterial infections in febrile neutropenic patients and to develop a specific risk score...
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditionsIssam I Raad
The M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
Clin Infect Dis 42:1398-403. 2006..Posaconazole is a broad-spectrum antifungal agent with in vitro and in vivo activity against Fusarium species...
Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centersCatherine Cordonnier
Hopital Henri Mondor, AP HP and Université Paris 12, France
Clin Infect Dis 42:955-63. 2006..The goal of this retrospective and consecutive survey was to assess prognostic factors of death due to IA after HSCT at the time of diagnosis of IA...
The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overviewJohn H Rex
AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom
Clin Infect Dis 39:S165-9. 2004..This supplement presents 12 articles by leading clinicians who are currently active in trials in this area and presents a current view of the unmet needs and challenges...
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 studySylvain Choquet
Hematology Unit, CHU La Pitié Salpêtrière Hospital, 47 bd de l Hopital, 75651 Paris Cedex 14, France
Blood 107:3053-7. 2006..We conclude that rituximab is effective and safe in PTLD, with stable responses at 1 year. The response rate and overall survival might be improved by combining rituximab with other treatments...
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcomeThomas F Patterson
Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
Clin Infect Dis 41:1448-52. 2005..In that trial, treatment with voriconazole or amphotericin B deoxycholate could be followed with other licensed antifungal therapies (OLAT). Here, we report the impact of OLAT on the outcome of patients with invasive aspergillosis...
Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosisJohn E Bennett
Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Clin Infect Dis 36:S113-6. 2003..An understanding of these features of design of antifungal drug trials is important in applying the results to clinical practice...
Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategyCatherine Cordonnier
Hematology Department, University Paris XII, Henri Mondor Hospital, 94000 Creteil, France
Clin Infect Dis 36:149-58. 2003..7 in the presence of 1, 2, and > or =3 parameters, respectively. Risk factors for staphylococcal and streptococcal infections differ among neutropenic patients. A simple scoring system for predicting streptococcal infection is proposed...
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on RBertrand Coiffier
Hematologie, CH Lyon Sud, 69495 Pierre Benite, France
J Clin Oncol 21:4402-6. 2003..This study was designed to evaluate the efficacy and the safety of rasburicase (recombinant urate oxidase) in adult patients with aggressive NHL during their first cycle of chemotherapy...
Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropeniaOlivier Lortholary
Universite Paris Descartes, Department of Infectious and Tropical Diseases, Centre d Infectiologie Necker Pasteur, Hopital Necker Enfants Malades, Paris, France
Lancet Infect Dis 8:612-20. 2008....
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) CBen de Pauw
Department of Blood Transfusion Service and Transplant Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Clin Infect Dis 46:1813-21. 2008..Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies...
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubtElias J Anaissie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Clin Infect Dis 43:1031-9. 2006
Mycograb for the treatment of invasive candidiasisRaoul Herbrecht
Clin Infect Dis 43:1083; author reply 1083-4. 2006
